Skip to content

US · MIRM · BIOTECHNOLOGY

Mirum Pharmaceuticals, Inc. (MIRM) intrinsic value and stock valuation

$96.13as of 2026-11-21 · Mkt cap 6.45B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Mirum Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values MIRM with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from MIRM’s statements →

Mirum Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Foster City, CA 94404 mirumpharma.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$521.3M
20182025
Net income
-$-23.36M
20182025
Free cash flow
$54.9M
20182025
Total equity
$314.7M+12.8% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$521.3M$336.9M$186.4M$77.1M$19.1M
Operating income-$-22.14M-$-87.61M-$-109.15M-$-131.22M-$-173.41M
Net income-$-23.36M-$-87.94M-$-163.41M-$-135.66M-$-83.99M
EPSd-$-465.34K-$-1.85M-$-4M-$-3.99M-$-2.77M
Operating cash flow$55.8M$10.3M-$-70.94M-$-120.14M-$-132.76M
Capital expenditure-$-950K-$-990K-$-20.11M-$-280K-$-19.02M
Free cash flow$54.9M$9.33M-$-91.05M-$-120.41M-$-151.78M
Total assets$842.8M$670.8M$646.6M$352.9M$294.7M
Total debt$319.5M$317.8M$308.1M$2.19M$2.61M
Net debt$22.8M$95.3M$21.8M-$-25.82M-$-28.73M
Total equity$314.7M$225.6M$248.7M$142M$120.2M
Cash and short-term investments$383.3M$280.3M$286.3M$151.7M$156.5M
Income statement
20252024202320222021
Revenue$521.3M$336.9M$186.4M$77.1M$19.1M
Cost of revenue$100.6M$81.6M$47M$12.4M$1.9M
Gross profit$420.7M$255.3M$139.3M$64.7M$17.2M
Research and development expenses$186.2M$140.6M$102.6M$106.8M$131.4M
Selling, general and administrative expenses$257M$202.2M$145.9M$89.1M$59.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$443.2M$342.9M$248.5M$195.9M$190.7M
Cost and expenses$543.5M$424.5M$295.5M$208.3M$192.6M
Interest income$12.7M$13.8M$13.7M$3.86M$370K
Interest expense$14.4M$14.3M$15.1M$16M$17.6M
Depreciation and amortization$24.2M$23.6M$10.8M$3.24M$970K
Ebitda$17.2M-$-48.97M-$-136.49M-$-122.85M-$-65.39M
Operating income-$-22.14M-$-87.61M-$-109.15M-$-131.22M-$-173.41M
Total other income/expenses, net$710K$690K-$-53.27M-$-10.85M$89.5M
Income before tax-$-21.43M-$-86.91M-$-162.42M-$-142.07M-$-83.95M
Income tax expense$1.94M$1.03M$990K-$-6.41M$40K
Net income-$-23.36M-$-87.94M-$-163.41M-$-135.66M-$-83.99M
Weighted average shares outstanding$50.2M$47.5M$40.9M$33.8M$30.3M
Weighted average diluted shares outstanding$50.2M$47.5M$40.9M$34M$30.3M
Balance sheet
20252024202320222021
Cash and short-term investments$383.3M$280.3M$286.3M$151.7M$156.5M
Net receivables$123.3M$78.3M$68M$24M$4.37M
Inventory$24.9M$22.4M$22.3M$5.57M$1.51M
Total current assets$549.7M$392.8M$387.5M$190.2M$166.6M
Property, plant and equipment, net$10.6M$9.81M$1.99M$2.35M$2.55M
Goodwill and intangible assets$260.9M$249.8M$252.9M$59M$18.7M
Long-term investments$8.11M$12.5M$0.00$0.00$4.98M
Total non-current assets$293.1M$278M$259.1M$162.7M$128.1M
Total assets$842.8M$670.8M$646.6M$352.9M$294.7M
Accounts payable$9.61M$14.6M$7.42M$8.69M$9.17M
Short-term debt$2.14M$1.71M$1.1M$930K$710K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$205.8M$126.6M$87.1M$64.7M$42.6M
Long-term debt$317.3M$316.1M$307M$1.26M$1.9M
Deferred revenue, non-current$0.00$0.00$0.00$140.4M$129.9M
Total non-current liabilities$322.3M$318.6M$310.9M$146.1M$131.8M
Capital lease obligations$9.65M$9.68M$1.72M$2.19M$2.61M
Total liabilities$528.1M$445.1M$398M$210.9M$174.4M
Common stock$10K$10K$10K$0.00$0.00
Retained earnings-$-667.54M-$-644.18M-$-556.24M-$-392.82M-$-257.16M
Accumulated other comprehensive income (loss)$350K-$-370K$1.64M-$-220K-$-40K
Total equity$314.7M$225.6M$248.7M$142M$120.2M
Total investments$94.8M$70.3M$0.00$123.7M$130.2M
Total debt$319.5M$317.8M$308.1M$2.19M$2.61M
Net debt$22.8M$95.3M$21.8M-$-25.82M-$-28.73M
Cash flow statement
20252024202320222021
Net income-$-23.36M-$-87.94M-$-163.41M-$-135.66M-$-83.99M
Depreciation and amortization$24.2M$23.6M$10.8M$3.68M$970K
Stock-based compensation$71.4M$48.4M$35M$27M$23.1M
Change in working capital-$-19.71M$22.6M-$-22.64M-$-21.05M$17M
Accounts receivable-$-48.05M-$-11.43M-$-43.97M-$-20.73M$0.00
Inventory-$-8.45M-$-3.17M-$-4.39M-$-3.45M-$-490K
Accounts payable$50.1M$40.3M$30.8M$7.64M$22.7M
Net cash provided by operating activities$55.8M$10.3M-$-70.94M-$-120.14M-$-132.76M
Investments in property, plant and equipment-$-950K-$-990K-$-110K-$-280K-$-19.02M
Acquisitions, net$0.00$0.00-$-212.76M-$-7.98M-$-19M
Net cash used for investing activities-$-23.95M-$-90.12M-$-107.2M$7.7M$48.6M
Common stock issued$40.1M$17.7M$216.7M$107.4M$6.91M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$40.1M$17.7M$336.6M$109.1M$73.5M
Net change in cash$75.2M-$-63.4M$158.3M-$-3.34M-$-10.75M
Cash at end of period$298.2M$222.9M$286.3M$128M$131.3M
Operating cash flow$55.8M$10.3M-$-70.94M-$-120.14M-$-132.76M
Capital expenditure-$-950K-$-990K-$-20.11M-$-280K-$-19.02M
Free cash flow$54.9M$9.33M-$-91.05M-$-120.41M-$-151.78M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Mirum Pharmaceuticals, Inc.

        Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

        CEO
        Christopher Peetz
        Employees
        372
        Beta
        0.48

        Explore

        Frequently asked questions

        What is the intrinsic value of Mirum Pharmaceuticals, Inc. (MIRM)?

        Mirum Pharmaceuticals, Inc. (MIRM) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MIRM undervalued?

        MIRM trades at a price of $96.13 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.